# To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

> **NCT01160822** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 169 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **BIOLOGICAL:** Canakinumab
- **DRUG:** Placebo to canakinumab
- **DRUG:** Naproxen
- **DRUG:** Placebo to Naproxen

## Key facts

- **NCT ID:** NCT01160822
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2012-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160822, "To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01160822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*